Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CRSP 
Crispr Therapeutics AG (CRSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CRSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -37.89% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.84B USD | Price to earnings Ratio - | 1Y Target Price 85.04 |
Price to earnings Ratio - | 1Y Target Price 85.04 | ||
Volume (30-day avg) 1935720 | Beta 1.76 | 52 Weeks Range 32.51 - 67.88 | Updated Date 04/2/2025 |
52 Weeks Range 32.51 - 67.88 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -180.96% |
Management Effectiveness
Return on Assets (TTM) -13.04% | Return on Equity (TTM) -19.2% |
Valuation
Trailing PE - | Forward PE 23.36 | Enterprise Value 1238772350 | Price to Sales(TTM) 76.18 |
Enterprise Value 1238772350 | Price to Sales(TTM) 76.18 | ||
Enterprise Value to Revenue 35.39 | Enterprise Value to EBITDA 14.16 | Shares Outstanding 85774496 | Shares Floating 84319739 |
Shares Outstanding 85774496 | Shares Floating 84319739 | ||
Percent Insiders 1.67 | Percent Institutions 77.72 |
Analyst Ratings
Rating 3.79 | Target Price 84.08 | Buy 4 | Strong Buy 11 |
Buy 4 | Strong Buy 11 | ||
Hold 11 | Sell - | Strong Sell 2 | |
Strong Sell 2 |
Upturn AI SWOT
Crispr Therapeutics AG
Company Overview
History and Background
CRISPR Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland. It focuses on developing gene-based medicines using CRISPR-Cas9 technology. The company has made significant progress in advancing its pipeline of therapeutic candidates and establishing strategic collaborations.
Core Business Areas
- Gene Editing Therapies: Develops therapies using CRISPR-Cas9 gene editing technology to treat genetic diseases.
- Allogeneic Cell Therapies: Creates off-the-shelf cell therapies for oncology and autoimmune diseases.
Leadership and Structure
Dr. Samarth Kulkarni is the CEO. The company has a board of directors and operates with research, development, and commercialization teams.
Top Products and Market Share
Key Offerings
- Exagamglogene autotemcel (exa-cel) (Vertex partnership): A CRISPR-Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. Approved by the FDA in December 2023 and EMA in Feb 2024. While exact market share data is unavailable, it is expected to dominate the market for gene therapies treating these conditions. Competitors include bluebird bio (BLUE) with gene therapies like Zynteglo (beta thalassemia) and Lyfgenia (sickle cell disease).
- CTX110: An allogeneic CAR-T cell therapy targeting CD19-positive B-cell malignancies. Currently in clinical trials. Market share is currently zero as it is pre-commercialization. Competitors are existing CAR-T therapies like Yescarta (GILD), Kymriah (NVS), and Tecartus (GILD).
Market Dynamics
Industry Overview
The gene editing and cell therapy industry is rapidly growing, driven by advancements in technology and increasing prevalence of genetic diseases and cancer.
Positioning
CRISPR Therapeutics is a leader in CRISPR-based gene editing, with a strong patent portfolio and clinical pipeline. The company benefits from early-mover advantage and strategic partnerships.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to reach billions of dollars within the next decade. CRISPR Therapeutics is well-positioned to capture a significant share of this market, especially with successful commercialization of exa-cel. The TAM for oncology cell therapies is also substantial.
Upturn SWOT Analysis
Strengths
- Pioneering CRISPR-Cas9 technology
- Strong intellectual property
- Strategic partnerships (e.g., Vertex)
- Advanced clinical pipeline
- FDA and EMA approval for exa-cel
Weaknesses
- High research and development costs
- Regulatory hurdles
- Manufacturing complexities
- Reliance on partners for commercialization in some regions
- Competition in gene therapy space
Opportunities
- Expanding pipeline to new therapeutic areas
- Developing next-generation CRISPR technologies
- Entering new markets
- Acquiring complementary technologies or companies
- Securing additional regulatory approvals
Threats
- Competition from other gene editing companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Intellectual property disputes
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BLUE
- EDIT
- NTLA
Competitive Landscape
CRISPR Therapeutics is a leading player in the gene editing field. Its competitive advantage lies in its CRISPR-Cas9 technology and strong partnership with Vertex (VRTX). The company faces competition from other gene editing and cell therapy companies with alternative technologies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by preclinical and clinical progress, along with partnership agreements.
Future Projections: Analysts expect significant revenue growth following regulatory approvals for exa-cel, with potential for further growth through pipeline expansion.
Recent Initiatives: Securing regulatory approvals for exa-cel, advancing clinical trials for CTX110 and other candidates, and expanding research collaborations.
Summary
CRISPR Therapeutics is a strong player in the gene editing space, bolstered by the FDA and EMA approval of Exa-cel and partnership with Vertex. High research and development costs remain a challenge, along with competition from other gene editing companies. Strategic expansion of their clinical pipeline and new market entries could prove to be beneficial going forward.
Similar Companies
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
NTLA
Intellia Therapeutics Inc
NTLA
Intellia Therapeutics Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- FDA Website
- EMA Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is an approximation and may vary depending on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crispr Therapeutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-10-19 | CEO & Chairman Dr. Samarth Kulkarni Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 393 | Website https://www.crisprtx.com |
Full time employees 393 | Website https://www.crisprtx.com | ||
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.